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Wedeterminedtheroleofinterleukin-1β(IL-1β)signalingontumornecrosisfactoralpha-induced(TNF-α)lungneutrophilinﬂux
as well as neutrophil chemoattractant macrophage inﬂammatory protein (MIP-2) and KC and soluble TNF-α receptor (TNFR)
levels utilizing wildtype (WT), TNF receptor double knockout (TNFR1/TNFR2 KO), and IL-1β KO mice after oropharyngeal
instillation with TNF-α. A signiﬁcant increase in neutrophil accumulation in bronchoalveolar lavage ﬂuid (BALF) and lung
interstitium was detected in the WT mice six hours after TNF-α exposure. This correlated with an increase in BALF MIP-2. In
contrast, BALF neutrophil numbers were not increased by TNF-α treatment of IL-1β KOs, correlating with a failure to induce
BALF MIP-2 and a trend toward increased BALF soluble TNFR1. TNF-α-instillation increased lavage and serum KC and soluble
TNFR2 irrespective of IL-1β expression. These results suggest IL-1β contributes, in part, to TNF-α-mediated, chemokine release,
and neutrophil recruitment to the lung, potentially associated with altered soluble TNFR1 release into the BALF.
Copyright © 2009 Sara Saperstein et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Inhalation of infectious agents results in an acute pulmonary
inﬂammatory response characterized by the recruitment and
accumulation of neutrophils, (polymorphonuclear, PMN)
cells, to the lung. This occurs through up-regulation of
adhesion molecules and chemotactic signals by various cell
types including epithelial, endothelial, and inﬂammatory
cells. Upon migration to the sites of infection or injury,
PMNs neutralize pathogens through phagocytosis and the
release of superoxide which is converted into microbiocidal
hypochlorous acid [1].
The importance of neutrophils in host defense has been
shown in many studies. For instance, mice treated with
inﬂuenza virus strain HK×31 rapidly recruited neutrophils
to the upper and lower airways where they played a critical
role in limiting virus replication during the early and later
phases of infection [2]. However, PMNs also contribute to
the pathogenesis of increased pulmonary vascular perme-
ability and lung injury through the release of proteases and
oxidants, thereby contributing to the development of acute
lung inﬂammatory diseases [3–6].
Thepleiotropicmediatorstumornecrosisfactor-α(TNF-
α) and interleukin-1β (IL-1β) are potent cytokines that play
an important role in acute and chronic lung inﬂammatory
diseases by inducing the production of various chemokines,
growth factors, and adhesion molecules like intercellular
adhesion molecule 1 (ICAM-1) [7–9]. TNF-α and IL-1β
are produced by similar cell types including macrophages,
PMNs, and epithelial cells. However, TNF-α interacts with
two distinct receptors, TNFR1 and TNFR2, to transduce
its biologic eﬀects whereas IL-1β signals through IL-1R1.
The two TNF receptors and the IL-1β decoy receptor, IL-
1 receptor antagonist or IL-1Ra, are proteolytically cleaved
from the cell surface by metalloproteases generating soluble
forms (sTNFR1, sTNFR2, and soluble IL-1Ra) with the2 Mediators of Inﬂammation
potential to antagonize the bioactivity of the soluble cognate
ligands [10–12].
Literature shows a role for IL-1β in modulating TNF-
α bioactivity; for instance, in human pulmonary cells IL-
1β induced TNFR1 release whereas in human gingival
ﬁbroblasts IL-1β enhanced sTNFR2 levels without alter-
ing shedding of TNFR1. Ex vivo/in vitro studies have
shown that IL-1β induced the expression of tracheal TNF
receptors time dependently [13–17]. Previously we have
shown in a pulmonary epithelial type II-like cell line
that IL-1β enhanced TNF-α-mediated expression of the
two neutrophil chemoattractants macrophage inﬂammatory
protein-2 (MIP-2) and KC at the transcriptional level in
associationwithincreasingsurfaceexpressionofbothTNFRs
thereby potentially contributing to the acute inﬂammatory
response induced by TNF-α [18].
The impact, however, of IL-1β on TNF-α-mediated lung
inﬂammation in vivo is incompletely deﬁned. In this study,
we utilized wildtype (WT) C57BL/6J and IL-1β KO mice to
examine the role of the interleukin on acute TNF-α-induced
interstitial lung neutrophil accumulation and inﬂux as well
as alterations in the levels of the two soluble TNF receptors
and secretion of MIP-2 and KC.
2.MaterialsandMethods
2.1.Wild-TypeandKnockoutMice. TNFRsf1a/1b(TNFR1/2)
d o u b l e - n u l lm i c ew e r er e g e n e r a t e di naC 5 7 B L / 6 Jb a c k -
ground. TNFRsf1atm1mak/j–/– and TNFRsf1b
tm1Mwm/J–/–
single-knockout (KO) mice [16] were each backcrossed 12
generations onto C57BL/6J and then interbred to produce
double-transgenic null mice. Wild-type (WT) C57BL/6J
mice were used as experimental controls (The Jackson
Laboratory). IL-1β−/− mice generated on a C57BL/6J
background were a kind gift from Dr. Yoichiro Iwakura at
the University of Tokyo. Mice used in the current protocol
were bred and maintained in microisolator cages in speciﬁc
pathogen-free rooms in the animal care facility at the
University of Rochester Medical Center (Rochester, NY).
Sentinel animals maintained in the same rooms, on bedding
mixed with bedding taken from other cages within the room,
routinely tested negative for common murine pathogens,
including murine hepatitis, pinworm, and Sendai virus. All
animal care and experimental protocols were approved by
the University of Rochester Committee on Animal Research
and follow the guidelines of IUCAC.
2.2. Treatment of Mice. Six-to-ten week-old mice were
lightly anesthetized via inhalation of isoﬂurane, prior to
oropharyngeal (OP) instillation (50μL) of saline as vehicle
control or recombinant murine truncated tumor necrosis
factor-α (rmTNF-α,5μg/50μL saline/mouse, R&D Systems,
Minneapolis, MN). Six hours after instillation, animals
were euthanized by intraperitoneal injection of sodium
pentobarbital (5mg/mouse) followed by exsanguination and
pneumothorax.
2.3. Analysis of Bronchoalveolar Lavage (BAL) and Cells
Isolated from BALF. For BAL ﬂuid collection, the trachea
was intubated, the anterior chest wall removed, and the
lungs lavaged with normal saline (room temperature, 1mL
× 10). The ﬁrst two lavage aliquots were centrifuged
at 300 × gf o r1 0m i n u t e sa t4 ◦C to pellet the har-
vested cells. The supernatant was frozen at −80◦C until
assayed for total protein by bicinchoninic acid assay (BCA,
Pierce, Rockford, IL) and for cytokines and receptors.
The remaining eight BALF aliquots were combined and
centrifuged. The supernatant was discarded. The pelleted
BALF cells from all ten aliquots were resuspended in
Hanks Balanced Salt Solution (HBSS). A total BALF cell
count was performed by hemocytometer. BALF cellular
diﬀerential was determined on 100μL cytospins stained with
Diﬀ-Quik (Dade Behring, Newark, DE). Lung homogenate
was prepared in radioimmunoprecipitation assay (RIPA)
buﬀer supplemented with an antiprotease cocktail tablet
(1tablet/10mLs, Roche Diagnostics, Indianapolis, IN). Total
protein content of the homogenates was determined by BCA
assay.
2.4. Analysis of Soluble TNFR1, Soluble TNFR2, MIP-2, and
KC. Lung protein homogenates, serum, and BALF were
analyzed by sandwich ELISA (R&D Systems) for soluble
TNF receptors, MIP-2, and KC according to manufacturer’s
instructions. BALF and lung homogenate values were nor-
malized to total protein of the samples assessed by BCA.
2.5. Examination of Interstitial Neutrophil Accumulation.
The left lung was inﬂation ﬁxed with 10% buﬀered for-
malin overnight, dehydrated to 70% ethanol, and paraﬃn
embedded. Tissue sections were deparaﬃnized and then
sequentially hydrated in passages through xylene, 100%
ethanol, 95% ethanol, 70% ethanol, and distilled water.
Samples were subjected to antigen retrieval with immersion
of slides in 1X Dako Target Retrieval Solution (DAKO,
Carpinteria, CA S16990, pH 6.0) and then blocked with 3%
hydrogen peroxide. After washing with TRIS-buﬀered salt
containing 0.1% Tween (TBS-T), slides were incubated for 1
hour in TBS-T containing 5% normal mouse serum at room
temperature and then further incubated overnight at 4◦C
in the dark in TBS-T containing rat antimouse neutrophil
allotypic marker antibody (1 : 100, Serotec, Raleigh, NC,
MCA771G). Next, slides were washed with TBS-T and then
incubated with Rat Probe (Rat on Mouse HRP-Polymer
kit, catalog number RT517H, Biocare Medical, Concord,
CA) for 15 minutes at room temperature. After washing
oﬀ excess with TBS-T, Rat Polymer-HRP (Biocare Medical)
was added for an additional 15 minutes. The slides were
rinsed again in TBS-T and staining was performed by the
addition of diaminobenzidine chromogen (DAB) substrate
(DAB Peroxidase Substrate kit, catalog number DB801L,
Biocare Medical) and then counterstained with hematoxylin
(Cat Hematoxylin, catalog number CATHE-MM, Biocare
Medical) and bluing solution (Bluing reagent, Richard-
Allan Scientiﬁc, Kalamazoo, MI, 7301) before dehydrating
again in 75% ethanol, 95% ethanol, and 100% ethanol
and ﬁnally xylene. The number of PMNs localized to the
lung interstitium was evaluated by MetaMorph softwareMediators of Inﬂammation 3
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Figure 1: Neutrophil accumulation in mouse lungs exposed to TNF-α. Wildtype (WT) or IL-1β knockout (−/−K O )m i c ew e r ei n s t i l l e di n t o
the oropharynx (OP) with saline (50μL) or rmTNF-α (5μgi n5 0μL saline/mouse). After 6 hours, lungs were formalin ﬁxed and neutrophil
antigen-positive cells were identiﬁed by immunohistochemistry (arrows). Images were captured through 10x objective. In the graphical
analysis, a neutrophil index was determined as the ratio of neutrophil-positive cells per total number of nuclei per low power ﬁeld. Three
to twelve random ﬁelds were analyzed per lung section. Data are represented as mean ± SEM, n = 9–11 lung sections per TNF group.
∗ represents P ≤ .05 versus saline controls or (brackets) between cytokine-treated mice.
(Molecular Devices, Downingtown, PA) which facilitated
counting of four to twelve random photomicrographs (10×)
from each experimental lung section; nine to eleven sections
were analyzed per experimental group. Interstitial PMNs
were counted and then normalized to total number of cells
within the ﬁeld.
2.6. TUNEL Stain. Tissue sections were deparaﬃnized and
rehydrated through graded ethanol as described above. Sec-
tions were then stained with the terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL)
method using the ApopTag Red In Situ apoptosis detec-
tion kit (catalog number S7165, Chemicon International,4 Mediators of Inﬂammation
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Figure 2: Detection of soluble receptors in WT and IL-1 β KO mice.W To rI L - 1 β KO mice were OP instilled with either saline (50μL) or
TNF-α (5μg/50μL/mouse). After 6 hours, serum, BALF, and lung homogenate were isolated and analyzed for ((a), (c), and (e)) TNFR1 or
((b), (d), and (f)) TNFR2 by ELISA, and for lavage and lung, normalized to protein in samples measured by BCA. Results are mean ± SEM,
(n = 8–15 mice per group). ∗ represents P ≤ .05 saline versus TNF-α-treatment of single strain or (brackets) for saline or cytokine-treated
comparisons between strains.
Billerica, MA) according to the instructions of the manu-
facturer. Slides were then washed four times (two minutes
each) with PBS then visualized by ﬂorescence microscopy
with a Texas Red ﬁlter cube. The TUNEL method labels
cells containing fragmented DNA, a hallmark of apoptosis.
Positivelabelingwasachievedbyaddingtheenzymeterminal
deoxynucleotidyl transferase (TdT) to catalyze a template-
independent addition of nucleotide triphosphates to the
3 -OH ends of fragmented DNA, forming an oligomer com-
posed of digoxigenin. A rhodamine conjugated, antidigoxi-
genin antibody was then added, nuclei were counterstained
with DAPI, and positive-labeled cells were evaluated byMediators of Inﬂammation 5
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Figure 3: Analysis of MIP-2 after TNF-α instillation.W To rI L - 1 β KO mice were OP instilled with either saline (50μL) or TNF-α
(5μg/50μL/mouse). After 6 hours, serum, BALF, and lung homogenate were isolated and analyzed for ((a), (b), and (c)) MIP-2 and ((d), (e),
and (f)) by ELISA. BALF and lung homogenate values are normalized to protein content measured by BCA. Results are mean ± SEM, (n =
8–15). ∗ represents P ≤ .05 saline versus TNF-α-treatment of single strain or (brackets) for saline or cytokine-treated comparisons between
strains.
examination of tissue sections using epiﬂuoresence at a
magniﬁcation of 20×. Cells undergoing apoptosis were
recognized by an intensely ﬂuorescent nucleus. For quan-
titative analysis, ﬂuorescent cells were counted in at least
4-5 sections per animal, and mean number of TUNEL-
positive (TUNEL+) cells per section was determined. All
observationsreportedarebasedonanalysisofmultipletissue
s e c t i o n sf r o m3t o1 2m i c ep e rg r o u p .
2.7.StatisticalAnalysis. TheresultswereanalyzedbyANOVA
followed by Fisher’s PLSD and Scheﬀe’s post hoc analyses
using StatView software (Acton, MA). All data in this study6 Mediators of Inﬂammation
Table 1:CellcountanddiﬀerentialofbronchoalveolarlavageharvestedsixhoursafteroropharyngealdeliveryofTNFalphaorcontrolsaline.
BAL: bronchoalveolar lavage; Lymphs: lymphocytes. Treatment groups represent 8–15mice/group.∗P ≤ .05 TNF versus saline, C57BL6/J
treatment groups; ‡P ≤ .05 IT TNF versus Saline, ILβ−/− treatment groups; #P ≤ .05 IT TNF, IL-1β−/− versus WT treatment groups. Values
are means ± SEM, n = 8 −15 mice.
Cell type
Group BAL Cell Count
(×104/mL) % Macrophages % Neutrophils % Lymphs Macrophage #
(×104/mL)
Neutrophil #
(×104/mL)
Lymph #
(×104/mL)
Saline, C57BL6/J 41.3 ±6.29 6 .0 ±1.22 .1 ±0.61 .9 ±0.93 9 .9 ±6.20 .86 ±0.30 .57 ±0.3
TNF, C57BL6/J 26.0 ±2.8
∗ 89.7 ± 2.0
∗ 8.5 ±2.0
∗ 1.9 ±0.72 9 .7 ±5.92 .23 ±0.4
∗ 0.65 ±0.3
Saline, IL-1β−/− 57.0 ±7.29 7 .7 ±0.81 .5 ±0.70 .8 ±0.35 6 .0 ±7.40 .66 ±0.30 .30 ±0.1
TNF, IL-1β−/− 39.8 ± 5.4
‡# 97.0 ±0.8# 1.6 ±0.5# 1.4 ±0.63 8 .7 ±5.40 .65 ±0.3# 0.46 ±0.2
are expressed as the mean ± SEM, n = 8–15 animals per
treatment group. A P value ≤ .05 was considered signiﬁcant.
3. Results
3.1. TNF-α Induces an Acute Neutrophilic Response in
Wildtype (WT) Mice That Is Deﬁcient in IL-1β Knockout
(KO) Mice. Oropharyngeal (OP) instillation of recombi-
nant murine truncated tumor necrosis factor-α (TNF-
α,5 μg/mouse) six hours prior to harvest resulted in a
signiﬁcant reduction in total cell number measured from
the bronchoalveolar lavage ﬂuid (BALF) of WT and IL-1β
KO animals, respectively, compared to saline-treated control
mice (Table 1). The reduction was greater in WT than in IL-
1β KO mice. This reduction was reﬂected in a decrease in
the percentage of the cells that were alveolar macrophages
(AMs) in TNF-α-treated WT mice as compared to saline-
treated WT and TNF-α-exposed IL-1β KO mice. The
absolute number of macrophages in the BALF also trended
downward although did not reach statistical signiﬁcance in
either TNF-treated strain. This was not associated with an
increase in the number of TUNEL positive cells measured by
TUNEL stain (data not shown). In the WT, the decrease in
percent macrophages correlated with a signiﬁcant increase
in neutrophils (PMN) as compared to saline WT control
mice as well as to TNF-α-treated IL-1β KO mice, both in
terms of percentage and in absolute number (Table 1). There
was no increase in BALF neutrophils in TNF-α-instilled,
as compared to saline-treated IL-1β KO mice. Finally, total
protein in the BALF was not signiﬁcantly altered in any
treatment group (data not shown). As control for the
speciﬁcity of the instilled TNF-α preparation, there were
no signiﬁcant eﬀects of TNF-α treatment in TNF receptor
double KO mice for all cellular and protein parameters tested
(data not shown). In summary, these data show that IL-1β
plays a role in the rapid recruitment of neutrophils to the
lung during TNF-α-mediated pulmonary inﬂammation.
3.2. TNF-α-Induced Increase in Interstitial Neutrophils in WT
Compared to IL-1β KO Mice. TNF-α induced a characteristic
inﬂammatory response that included increased neutrophil
index, deﬁned as the ratio of neutrophil-antigen positive
cells to total number of cell nuclei per low-power ﬁeld,
detected within the lungs of mice regardless of genotype
(Figure 1(e)). These neutrophil-antigen positive cells were
found throughout the parenchyma in addition to within
blood vessels and minimally in large conducting airways
(Figures 1(a)–1(d)). However, quantiﬁcation of the extent of
neutrophil accumulation revealed that WT, TNF-α-instilled
animals had signiﬁcantly greater recruitment of interstitial
PMNs compared to TNF-α-treated IL-1β KO mice. The
average neutrophil index of control, saline-treated WT and
IL-1β KO mice was 4 ± 3% and 2 ± 1.7% (mean ± SD),
respectively, consistent with that seen in normal, untreated
animals, as compared to 33% ± 12% and 21% ± 14.7% in
TNF-α-instilled mice. Neutrophil accumulation was noted
within alveolar walls and within vessels of TNF treated mice,
more uniformly in WT than in IL-1β deﬁcient animals.
3.3. Eﬀects of TNF-α on Soluble TNF Receptors between
WT and IL-1β KO Mice. TNF receptors are cleaved by
metalloproteases from the cell surface to create soluble forms
capable of binding TNF-α [19, 20]. Previously, it has been
shown that IL-1β modulates TNF receptor shedding in vitro,
thereby impacting cell responsiveness to TNF-α [18]. In
order to determine the in vivo role of IL-1β expression on
ligand-induced TNF receptor shedding, measurements of
both soluble (sTNFRs) TNFR1 and sTNFR2 were analyzed
in lung homogenate, serum, and BALF in response to
saline and TNF-α. As expected, sTNFRs were not detectable
in TNF receptor double KO animals (data not shown).
Interestingly, serum,BALF,andlung sTNFR1concentrations
tended to be lower in the saline treated IL-1β null mice
as compared to WT (Figures 2(a), 2(c), 2(e)). Following
TNF-α treatment, serum sTNFR1 levels were either slightly
or signiﬁcantly increased in WT and IL-1β KO animals,
respectively, although there were no diﬀerences between
TNF-α-exposed animals. BALF sTNFR1 levels tended to be
increased in IL-1β KO animals compared to both saline
controls and WT and TNF-α-treated mice though this did
notreachstatisticalsigniﬁcance.Interestingly,BALFsTNFR1
levels were unchanged from control in TNF-α treated WT
animals (Figure 2(c)). Similar to our previous studies in
a lung epithelial cell line in vitro [18], both transgenic
mice had a signiﬁcant decrease in lung sTNFR1 after TNF-
α exposure, although there were no diﬀerences between
TNF-α-exposed animals (Figure 2(e)). While there were no
diﬀerences in lung or BALF sTNFR2 between treatment orMediators of Inﬂammation 7
genotype, sTNFR2 was markedly increased in the serum
of both animal strains treated with TNF-α as compared to
saline controls (Figures 2(b), 2(d), 2(f)). Together these data
suggest that while IL-1β e x p r e s s i o nd o e sn o ti m p a c tT N F - α-
mediated sTNFR2, the interleukin may play a negative role
in the release of serum and BALF-derived, ligand-mediated
TNFR1.
3.4. Reduced BALF MIP-2 from TNF-α-Exposed IL-1β
KO Mice Compared to WT Animals. The two neutrophil
chemoattractant proteins MIP-2 and KC are induced by
both TNF-α and IL-1β in response to inﬂammatory stimuli
such as silica or infection [21] .I no r d e rt od e t e r m i n e
whether IL-1β-mediated alterations in PMN recruitment
and interstitial accumulation correlated with alterations in
TNF-α-mediated chemokine production, MIP-2 and KC
were evaluated from the BALF, serum, and lungs. As shown
in Figure 3(a), serum MIP-2 was signiﬁcantly increased in
both TNF-α-treated IL-1β KO and WT animals. However,
BALF-derived MIP-2 was only signiﬁcantly increased in
TNF-α-instilled WT mice while BALF MIP-2 from TNF-α-
treated IL-1β KO animals was not greater than saline-treated
controls and was depressed relative to WT, suggesting that
IL-1β plays a role in TNF-α-induced production of MIP-2
found in the BALF (Figure 3(b)). Finally, although markedly
increased compared to saline controls, lung MIP-2 levels
were no diﬀerent between transgenic animals treated with
TNF-α (Figure 3(c)). As shown in Figures 3(d)–3(f), serum,
BALF, and lung KC content markedly increased after TNF-α
treatment compared to saline controls but reached levels that
were not diﬀerent between WT or IL-1β KO animals.
4. Discussion
Tumor necrosis factor-α (TNF-α) is a pleiotropic cytokine
essential for lung immune and inﬂammatory responses to
microbial challenge [22, 23]. Inappropriate induction or
sustained activation of TNF-α signaling has been linked
to the development of acute and chronic lung disor-
ders characterized by the activation of resident cells and
subsequent migration and accumulation of immune cells
including macrophages and neutrophils [8, 24–26]. Due
to the consistent association between neutrophils and lung
injury in humans and animal models, and the propensity
of neutrophils and their products to cause tissue injury in
experimental systems, it has been theorized that PMNs play
an important role in the development of acute lung injury
(ALI) [25, 26].
TNF-α mediates inﬂammatory cell recruitment in
part by inducing the expression of chemokines including
macrophage inﬂammatory protein-2 (MIP-2) and KC by
activating two unique receptors, TNFR1 and TNFR2. MIP-2
and KC are potent neutrophil chemoattractants that belong
to the same (CXC) family of chemokines and that are
produced in the mouse at sites of tissue inﬂammation after
infection or injury [27, 28]. We recently reported, in a
murine lung epithelial cell line, that TNF-α up-regulates
surface expression and shedding of TNFR2 while down-
regulating TNFR1 in association with enhanced mRNA
expression and secretion of MIP-2 and KC [18].
However, in addition to TNF-α, early high levels of
another proinﬂammatory cytokine, interleukin-1β (IL-1β)
have been found in murine models of ALI [17, 18]. IL-
1β shares many of the biological properties of TNF-α,
including induction of chemokine expression, and studies
have shown that it also modulates shedding and mRNA
expression of TNF receptors [13, 19]. In murine lung
epithelial cells, IL-1β enhanced TNF-α-mediated MIP2 and
KC by increasing surface expression of lung epithelial TNF
receptors [18]. Based on these observations, the present
study investigated the hypothesis that IL-1β enhances TNF-
α-induced neutrophil recruitment to the lung by altering
TNF receptors as well as MIP-2 and KC production.
We found, in wildtype (WT) C57Bl/6J mice that oropha-
ryngealinstillationwithTNF-αenhancedthepercentageand
absolute number of PMNs in the lavage ﬂuid (BALF) and
within the interstitium which corresponded with a decrease
in the percentage of BALF alveolar macrophages as well as
t o t a ll a v a g ec e l ln u m b e r .T N F - α also mediates cell death pro-
cesses in addition to its inﬂammatory function in immune
cells; therefore this was regarded as a potential mechanism
behind the decrease in BALF cell number. TUNEL staining
was performed to assess apoptosis; however TNF-α exposure
did not detectably enhance TUNEL positive-stained cells
within the lungs of animals. Further analysis speciﬁcally of
lavage-derived cells, including activation and adherence to
or transmigration through airway epithelium, may aid in
elucidating mechanisms behind the TNF-α-mediated acute
decrease in BALF cell number.
In accordance with previous ﬁndings, TNFR1 was
decreased in the TNF-α-treated lungs while sTNFR2 was
enhanced in lavage (trend) and serum correlating with an
increase in BALF, serum, and lung MIP-2 and KC [29]. These
ﬁndings are consistent with the response of lung epithelial
cell lines to TNF-α in vitro [18]. However, we also found
that in contrast with our recent ﬁndings, lung TNFR2 levels
werenotalteredbetweensalineandTNF-α-treatedWTmice,
while lavage sTNFR1 tended to be increased in the TNF-
α-treated WT [18]. The discrepancies between in vivo and
in vitro systems may be due to several factors. First, the
numerous cell types in the airway accessible to lavage as
well as in the lung parenchyma, including macrophages,
potentially regulate TNF receptor shedding in response to
ligand diﬀerentially from the epithelial cells studied in vitro.
In addition, sTNF receptors may accumulate in culture
media whereas mice have the ability to mobilize shed
receptors into the circulation where they can be eliminated
via urination [30]. Likewise, serum soluble receptor content,
which is the summation of receptor release from numerous
cell types in various organ systems, is balanced by renal
clearance and thus may not reﬂect as well solubilization
occurring in the airway. In addition, the relatively low
TNFR2 content detected in the lung tissue homogenates may
suggest that despite, or perhaps due to, detergents in the
lysis buﬀer, the receptor in these samples may not have been
readily available to the assay system and content may be8 Mediators of Inﬂammation
under-estimated. Interestingly, in the process of this study
it was noted that addition of some preparations of bovine
serum albumin to TNFR2 standards prior to ELISA masked
the protein from detection (data not shown). The dilution
of serum and BALF samples prior to analysis appeared to
overcome this inhibition.
With regards to IL-1β KO mice, loss of interleukin
expression resulted in a trend towards constitutively reduced
BALF, lung, and serum sTNFR1 compared to WT mice.
BALF and serum MIP-2 were also slightly lower in KO
mice instilled with saline. Further study may uncover a
role for IL-1β in basal TNFR1 expression. Investigation into
the role of IL-1β in TNF-α-mediated events demonstrated
that IL-1β KO animals had a deﬁcient neutrophilic (PMN)
inﬂammatory response, as measured in both BALF and in
lung interstitium, after TNF-α instillation which correlated
withareductioninBALF-derivedmacrophageinﬂammatory
protein-2(MIP-2)measuredatthesametimepoint.Noclear
evidence for a role of IL-1β in TNF-α-induced shedding of
s o l u b l eT N Fr e c e p t o r sw a sd e t e c t e di nt h i ss t u d y .O v e r a l l ,
these ﬁndings are consistent with previous studies which
demonstrated that IL-1β is critical for pulmonary inﬂam-
mation and ﬁbrosis [31–34]. However, it is noted that the
loss of IL-1β was insuﬃcient to prevent the TNF dependent
induction of BALF, serum, and lung-derived KC as well as
serum and lung-MIP-2.
It is not clear why the lack of IL-1β reduced TNF-
mediated accumulation of MIP-2 and neutrophils in BALF.
Perhaps the TNF-α-induced activation of interstitial PMNs
and macrophages in either genotype contributed to the
increase in lung-MIP-2 whereas airway cells are responsible
for lavagable MIP-2 and transmigration of neutrophils.
Likewise, parenchymal cells may have played a role in up-
regulating KC in BALF and lung, which was not aﬀected by
loss of IL-1β.T om o r es p e c i ﬁ c a l l ya d d r e s sc e l lt y p es p e c i ﬁ c
response origins in vivo, experiments utilizing chimeric mice
in which IL-1β or its receptor, IL-1RI, is present only on
parenchymal or inﬂammatory cells, such as by irradiating
and then transplanting animals with bone marrow of
reciprocal transgenic mice, could further aid in interpreting
the up-regulation of individual chemokines after TNF-α
stimulation. For instance, Pryhuber et al. demonstrated
that parenchymal cell TNF receptor expression was key to
inﬂammatory cell recruitment and respiratory failure in
Pneumocystis carinii-induced pneumonia [35]. In addition,
diﬀerential temporal regulation of each chemokine has also
been demonstrated. Studies inoculating mice with Legionella
pneumophila showed that levels of KC peaked one day
earlier than MIP-2 while still other investigators have found
overlapping production of each chemokine in models of
inﬂammation [36–38]. It is possible that the time-point
selected for the present study misses IL-1β-modiﬁcation of
TNF-α-induced KC.
It is also possible that the interleukin-mediated con-
tribution to TNF-α cytokine production is redundant. For
example, the related IL-1α may enhance the induction of
KC found in the BALF and lungs of both WT and IL-1β
null mice. Studies have shown that IL-1α plays a role in
stabilizing KC mRNA, primarily through IRAK1 [39–41].
Moreover, Son and Roby showed, in granulosa cells isolated
from immature mice at 28 days of age, that exposure to IL-
1α induced KC mRNA and protein [42]. Studies of TNF-
α-induced lung inﬂammatory response in IL-1 receptor
deﬁcient mice or in the presence of IL-1RI antagonists may
clarify the role of both IL-1α and β.
Inhibition of interleukin signaling has been shown to
be eﬃcient in treating several destructive diseases such
as systemic onset juvenile idiopathic arthritis, hereditary
periodic fever syndromes, and gout arthritis [43–46]. Our
results, showing the role of IL-1β in modifying TNF-α-
induced pulmonary inﬂammation, are in support of a
consideration for IL-1β neutralization in treatment of acute,
and potentially chronic, TNF-α mediated lung diseases.
Therefore, in pulmonary diseases characterized by neu-
trophil accumulation and excessive inﬂammation, loss of
IL-1β bioactivity may be useful in modulating pulmonary
inﬂammatory diseases, potentially without increasing the
risk of serious adverse secondary eﬀects such as pulmonary
infections which are seen in rheumatoid arthritis (RA) and
Crohn’s disease (CD) patients using anti-TNF-α therapeutic
agents.
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